Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This case report describes a patient who developed multiple skin reactions, including eczematous lesions and alopecia areata, during adalimumab treatment, but found no improvement in pustulosis palmoplantaris with different biologics.

This review highlights recent advances in pediatric dermatologic treatments, including the use of propranolol for infantile hemangiomas and etanercept for plaque psoriasis, but it reports no new clinical results.

This case report highlights a potential association between etanercept, a TNF-α blocker, and the onset of alopecia areata, suggesting complex interactions between anti-TNF-α treatments and hair follicle growth.

This study reported improvement of psoriatic onychopachydermoperiostitis symptoms with the use of etanercept.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

This article reviews the centenary of the British Association of Dermatologists by highlighting significant papers from its journals, with no new clinical results reported.

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.

This article discusses psoriasis, highlighting its common triggers, such as trauma and infections, and potential treatment options ranging from topical therapies to systemic medications like methotrexate for severe cases.

This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.

This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.

This review outlines the changing landscape of psoriasis vulgaris treatment with biologics, which offer benefits but also have increasingly recognized adverse effects, without presenting new clinical results.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This article examines anticytokine therapies for autoimmune diseases, highlighting the potential of anti-interferon-γ as a universal treatment for certain conditions and noting varying effectiveness of tumor necrosis factor-α inhibitors.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

This abstract does not report specific research results but introduces a book focusing on the intersection of endocrinology and aesthetic medicine and its growing importance in contemporary clinical practice.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This study suggests that methotrexate use among rheumatoid arthritis patients is associated with patient-reported side effects and tolerability issues that may not be fully recognized by physicians.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.